News Wire

Major drug companies implemented big price increases in the U.S.—in some cases more than doubling listed charges—for widely used medications during the past five years, according to an exclusive report from Reuters. Prices for four of the nation’s top 10 drugs increased more than 100% since 2011,…
More than 300 local, state, and federal government officials, health experts, and nongovernment partners gathered April 1 at the Centers for Disease Control and Prevention (CDC) to prepare for the likelihood of mosquito-borne transmission of the Zika virus in some parts of the continental United States.…
Statins may significantly reduce adverse cardiovascular events in people with average cholesterol and blood pressure (BP) levels who are considered to be at intermediate risk for cardiovascular disease, while the use of BP-lowering medications may be beneficial only in hypertensive patients, according…
The FDA has extended the action date for its review of the new drug application for an oral formulation of methylnaltrexone bromide (Relistor, Valeant Pharmaceuticals International) by three months to July 19, 2016. The FDA extended the date to allow a full review of new information submitted by Valeant…
New three-year data on Saxenda (liraglutide [rDNA origin] injection, Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist, have been presented at the Endocrine Society’s 98th Annual Meeting and Exposition, held in Boston, Massachusetts. The phase 3a SCALE (Satiety and Clinical Adiposity––Liraglutide…
An estimated one in 68 (14.6 per 1,000) school-aged children have been identified with autism spectrum disorder (ASD) in the United States, according to the Centers for Disease Control and Prevention (CDC). The agency’s surveillance summary, published in Morbidity and Mortality Weekly Report, shows…
The blood-testing devices that Theranos Inc. has touted as revolutionary often failed to meet the company’s own accuracy requirements for a range of tests, including one to help detect cancer, according to an article in the Wall Street Journal. The Journal got an early look at a federal report detailing…
The blood-testing devices that Theranos Inc. has touted as revolutionary often failed to meet the company’s own accuracy requirements for a range of tests, including one to help detect cancer, according to an article in the Wall Street Journal. The Journal got an early look at a federal report detailing…
A team led by Purdue University researchers is the first to determine the structure of the Zika virus. The findings provide insights critical to the development of effective antiviral treatments and vaccines, according to the investigators. Their report was published in Science. The team also identified…
Parkland Hospital, an 800-bed safety-net facility serving Dallas County, Texas, is teaching uninsured patients how to self-administer intravenous (IV) antibiotics for outpatient parenteral antimicrobial therapy (OPAT), and the innovative approach appears to be paying off. The program lowered 30-day…
Two phase III, placebo-controlled studies evaluating dupilumab (Regeneron Pharmaceuticals/Sanofi) in adults with inadequately controlled moderate-to-severe atopic dermatitis (AD) have met their primary endpoints. In the studies, known as LIBERTY AD SOLO 1 and SOLO 2, treatment with dupilumab as monotherapy…
The FDA has granted marketing approval for defibrotide sodium (Defitelio, Jazz Pharmaceuticals) 80 mg/mL for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome, with renal or pulmonary dysfunction following hematopoietic…
In a multicenter, randomized clinical trial, former prisoners who received six monthly injections of extended-release naltrexone (Vivitrol, Alkermes, Inc.)––a medication that blocks opioid receptors in the brain––were significantly less likely to resume opioid use than were those who received…
The diabetes drug pioglitazone (Actos, Takeda Pharmaceuticals) is associated with an increased risk of bladder cancer, according to a study published in the British Medical Journal. The findings suggest that the risk increases with increasing duration of use and dose. No increased risk was seen for…
Positive results have been reported from a pivotal phase 3 study of baricitinib (Eli Lilly/Incyte Corporation), a once-daily oral medication under regulatory review for the treatment of patients with moderate-to-severe rheumatoid arthritis (RA). The study met its primary endpoint of an improved ACR20…

Pages